Aimmune Therapeutics Inc. (Nasdaq: AIMT), the Brisbane, Calif.-based biotech that's developed one of the first true treatments for peanut-allergy sufferers, is scheduled to make its public debut today.
The firm's shares are supposed to start trading today after an initial public offering (IPO) of 8.33 million shares in a price range of $14 a share to $16 a share.
Although we don't often recommend IPO stocks, we made an exception here in a special report we gave you back on July 27. Aimmune is a development-stage biotech, but its lead product is about to enter late-stage clinical trials.
With the stock scheduled to begin trading today, let's take another look at the firm, its lead product - and the market it's looking to serve.Full Story
This is premium content for Private Briefing subscribers only.